Insulin Lispro shortage — US supply status & alternatives

Insulin Lispro

—

🇦🇺 AUST R 53466 · Eli Lilly Australia Pty Ltd

In supply · Australia

Humalog Tempo Pen

In supply · 🇦🇺 Australia · short in🇺🇸 US🇨🇦 CA🌐 EU🇳🇴 NO

In supply in Australia

Reading today’s signals…

🇦🇺 AUAEMPA$16.33DPMQ A$99.49details →

✓ Can I substitute?

Per normal rules

Confirm with prescriber

⇄ Best alternative

None listed

refer to prescriber

◷ Expected back

No estimate

No estimate provided

Product attributes reference data we hold

Active ingredient (INN)	Insulin Lispro
Brand names	Humalog Tempo Pen
Therapeutic category	Auto-created by U.S. Food and Drug Administration — Drug Shortages scraper
Controlled substance	No
Marketing-authorisation holders	Eli Lilly and Company, Eli Lilly Australia Pty Ltd, Sanofi Winthrop Industrie
Registrations on file	10
Patient information leaflet (PIL)	Not on file
Summary of product characteristics (SPC)	Not on file

Trade price 🇦🇺 PBS · July 2026

🇦🇺 AU

● Official price on file

Ex-manufacturer

A$16.33

AEMP

Dispensed (DPMQ)

A$99.49

incl. fees

Pack

insulin lispro 100 units/mL injection, 1 x 10 mL vial

Source: PBSEffective July 2026 · AUD

Other markets

🇺🇸 US

US$10.20

Acquisition

Substitution pathways 🇦🇺 Australia · TGA

—

No substitution instrument in force

Dispense per normal rules, or refer to the prescriber. No active SSSI/S19A instrument detected for this medicine.

Shortage status by regulator official notices

🇺🇸

United States

FDA · 3h ago

Critical

🇨🇦

Canada

HC · 13h ago

High

🌐

EMA · 1d ago

High

🇳🇴

Norway

NOMA · 3d ago

Medium

Recalls official enforcement reports

🇺🇸

HUMALOG

Eli Lilly & Company · Mar 2024

Class IIdetails ↗

🇺🇸

ADMELOG

Sanofi-Aventis U.S. LLC · Apr 2023

Class IIdetails ↗

🇺🇸

HUMALOG

Cardinal Health Inc. · Apr 2022

Class Idetails ↗

🇺🇸

ADMELOG

Sanofi-Aventis U.S. LLC · July 2018

Class IIdetails ↗

🌐

Liprolog

Eli Lilly and Company Limited · Feb 2001

Class Unifieddetails ↗

Verified timeline regulator events

🇨🇦 26 May 2026

high reported

🇳🇴 4 Mar 2026

medium reported

🇳🇴 31 Oct 2025

medium reported

🇺🇸 24 Oct 2025

critical reported

🇳🇴 1 Sept 2025

medium reported

🌐 12 Aug 2025

high reported

Registration recordmarketing-authorisation holders

Registrations & marketing-authorisation holders10 registrations · 3 MA holders

Product	Strength	Form	Market	MA holder	Status
Insulin Lispro	100[iU]/mL	injection	🇺🇸 US	Eli Lilly and Company	Active
Protamine and	100[iU]/mL	injection	🇺🇸 US	Eli Lilly and Company	Active
HUMALOG insulin lispro	100 IU	—	🇦🇺 AU	Eli Lilly Australia Pty Ltd	Active
HUMALOG KwikPen insulin lispro	100 IU	—	🇦🇺 AU	Eli Lilly Australia Pty Ltd	Active
HUMALOG MIX25 insulin lispro	100 IU	—	🇦🇺 AU	Eli Lilly Australia Pty Ltd	Active
HUMALOG MIX25 KwikPen insulin lispro	100 IU	—	🇦🇺 AU	Eli Lilly Australia Pty Ltd	Active
HUMALOG MIX50 insulin lispro	100 IU	—	🇦🇺 AU	Eli Lilly Australia Pty Ltd	Active
HUMALOG MIX50 KwikPen insulin lispro	100 IU	—	🇦🇺 AU	Eli Lilly Australia Pty Ltd	Active
HUMALOG U200 KwikPen insulin lispro	200 IU	—	🇦🇺 AU	Eli Lilly Australia Pty Ltd	Active
Insulin lispro Sanofi	—	—	🌐 EU	Sanofi Winthrop Industrie	Active

For health-professional reference only. Mederti aggregates shortage and substitution information from official regulatory sources. It is not clinical advice and data may be incomplete or delayed. Confirm any substitution or supply decision against the primary regulator source, the prescriber, and current clinical references (e.g. AMH) before acting. Terms.